CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
Despite widespread deregulation of CDK4/6 activity in non-small cell lung cancer (NSCLC), clinical trials with CDK4/6 inhibitor (CDK4/6i) as a monotherapy have shown poor antitumor activity. Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during ra...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003577 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591876285267968 |
|---|---|
| author | Carlos M Roggero Anwesha B Ghosh Anvita Devineni Shihong Ma Eliot Blatt Ganesh V. Raj Yi Yin |
| author_facet | Carlos M Roggero Anwesha B Ghosh Anvita Devineni Shihong Ma Eliot Blatt Ganesh V. Raj Yi Yin |
| author_sort | Carlos M Roggero |
| collection | DOAJ |
| description | Despite widespread deregulation of CDK4/6 activity in non-small cell lung cancer (NSCLC), clinical trials with CDK4/6 inhibitor (CDK4/6i) as a monotherapy have shown poor antitumor activity. Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during radiotherapy. Since PARP1 expression was also significantly upregulated in NSCLC, we analyzed the efficacy of combining PARP1 and CDK4/6 inhibition in NSCLC models. We found that CDK4/6is synergize with PARP1 inhibitors (PARPis) to inhibit the clonogenic growth of RB-proficient NSCLC models. This synergy correlates with increased accumulation of DNA damage, interrupted cell-cycle checkpoints, and enhanced apoptotic cell death. Mechanistically, we showed that CDK4/6is promote PARP1 protein degradation, which lead to decreased availability of DNA repair factors involved in homologous recombination and suppression of DNA repair competency. Furthermore, we showed that PARP trapping is engaged in this synergy. We then confirmed that combining PARPi and CDK4/6i blocked the growth of NSCLC xenografts in vivo and patient-derived explant models ex vivo. Our data reveal a previously uncharacterized impact of CDK4/6i on PARP1 levels in RB-proficient NSCLC models and the engagement of PARP trapping in the synergy between CDK4/6i and PARPi. Our findings suggest combining CDK4/6i with PARPi could be a viable therapeutic strategy for patients with RB-proficient NSCLC. |
| format | Article |
| id | doaj-art-df6a0cd7738e44f882139384f25dd5ff |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-df6a0cd7738e44f882139384f25dd5ff2025-01-22T05:41:24ZengElsevierTranslational Oncology1936-52332025-02-0152102231CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancerCarlos M Roggero0Anwesha B Ghosh1Anvita Devineni2Shihong Ma3Eliot Blatt4Ganesh V. Raj5Yi Yin6Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States; Instituto de Histología y Embriología de Mendoza (IHEM)-CONICET-Universidad Nacional de Cuyo, ArgentinaDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United StatesDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United StatesDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United StatesDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United StatesDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United StatesDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States; Corresponding author at: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States.Despite widespread deregulation of CDK4/6 activity in non-small cell lung cancer (NSCLC), clinical trials with CDK4/6 inhibitor (CDK4/6i) as a monotherapy have shown poor antitumor activity. Preclinical studies indicate that CDK4/6i may collaborate by influencing DNA damage repair pathways during radiotherapy. Since PARP1 expression was also significantly upregulated in NSCLC, we analyzed the efficacy of combining PARP1 and CDK4/6 inhibition in NSCLC models. We found that CDK4/6is synergize with PARP1 inhibitors (PARPis) to inhibit the clonogenic growth of RB-proficient NSCLC models. This synergy correlates with increased accumulation of DNA damage, interrupted cell-cycle checkpoints, and enhanced apoptotic cell death. Mechanistically, we showed that CDK4/6is promote PARP1 protein degradation, which lead to decreased availability of DNA repair factors involved in homologous recombination and suppression of DNA repair competency. Furthermore, we showed that PARP trapping is engaged in this synergy. We then confirmed that combining PARPi and CDK4/6i blocked the growth of NSCLC xenografts in vivo and patient-derived explant models ex vivo. Our data reveal a previously uncharacterized impact of CDK4/6i on PARP1 levels in RB-proficient NSCLC models and the engagement of PARP trapping in the synergy between CDK4/6i and PARPi. Our findings suggest combining CDK4/6i with PARPi could be a viable therapeutic strategy for patients with RB-proficient NSCLC.http://www.sciencedirect.com/science/article/pii/S1936523324003577DNA damage repairCDK4/6 inhibitionPARP inhibitionPatient-derived explantNon-small cell lung cancer |
| spellingShingle | Carlos M Roggero Anwesha B Ghosh Anvita Devineni Shihong Ma Eliot Blatt Ganesh V. Raj Yi Yin CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer Translational Oncology DNA damage repair CDK4/6 inhibition PARP inhibition Patient-derived explant Non-small cell lung cancer |
| title | CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer |
| title_full | CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer |
| title_fullStr | CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer |
| title_full_unstemmed | CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer |
| title_short | CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer |
| title_sort | cdk4 6 inhibitors promote parp1 degradation and synergize with parp inhibitors in non small cell lung cancer |
| topic | DNA damage repair CDK4/6 inhibition PARP inhibition Patient-derived explant Non-small cell lung cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1936523324003577 |
| work_keys_str_mv | AT carlosmroggero cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT anweshabghosh cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT anvitadevineni cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT shihongma cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT eliotblatt cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT ganeshvraj cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer AT yiyin cdk46inhibitorspromoteparp1degradationandsynergizewithparpinhibitorsinnonsmallcelllungcancer |